胆固醇与冠心病的百年历程：从斑块到基因再到他汀类药物
A century of cholesterol and coronaries: from plaques to genes to statins.
作者信息
Goldstein Joseph L, Brown Michael S
机构信息
Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
出版信息
Cell. 2015 Mar 26;161(1):161-172. doi: 10.1016/j.cell.2015.01.036.
Abstract
One-fourth of all deaths in industrialized countries result from coronary heart disease. A century of research has revealed the essential causative agent: cholesterol-carrying low-density lipoprotein (LDL). LDL is controlled by specific receptors (LDLRs) in liver that remove it from blood. Mutations that eliminate LDLRs raise LDL and cause heart attacks in childhood, whereas mutations that raise LDLRs reduce LDL and diminish heart attacks. If we are to eliminate coronary disease, lowering LDL should be the primary goal. Effective means to achieve this goal are currently available. The key questions are: who to treat, when to treat, and how long to treat.
摘要
在工业化国家，四分之一的死亡是由冠心病导致的。一个世纪的研究已揭示出其主要致病因素：携带胆固醇的低密度脂蛋白（LDL）。LDL由肝脏中的特定受体（LDLR）控制，这些受体可将其从血液中清除。消除LDLR的突变会使LDL升高，并在儿童期引发心脏病发作，而增加LDLR的突变则会降低LDL并减少心脏病发作。如果我们要消除冠心病，降低LDL应是首要目标。目前已有实现这一目标的有效方法。关键问题是：治疗谁、何时治疗以及治疗多久。
相似文献
1
A century of cholesterol and coronaries: from plaques to genes to statins.
Cell. 2015 Mar 26;161(1):161-172. doi: 10.1016/j.cell.2015.01.036.
2
Atherosclerosis: Making a U Turn.
Annu Rev Med. 2020 Jan 27;71:191-201. doi: 10.1146/annurev-med-042418-011108.
3
Hypercholesterolemia: The role of PCSK9.
Arch Biochem Biophys. 2017 Jul 1;625-626:39-53. doi: 10.1016/j.abb.2017.06.001. Epub 2017 Jun 3.
4
Statins and the coronary plaque calcium "paradox": Insights from non-invasive and invasive imaging.
Atherosclerosis. 2015 Aug;241(2):783-5. doi: 10.1016/j.atherosclerosis.2015.05.021. Epub 2015 Jun 3.
5
Rosuvastatin Reduces Aortic Sinus and Coronary Artery Atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)/ApoE (Apolipoprotein E) Double Knockout Mice Independently of Plasma Cholesterol Lowering.
Arterioscler Thromb Vasc Biol. 2018 Jan;38(1):26-39. doi: 10.1161/ATVBAHA.117.305140. Epub 2017 Nov 21.
6
The impact of statins treatments for plaque characteristics in stable angina pectoris patients with very low and high low-density lipoprotein cholesterol levels: an intracoronary optical coherence tomography study.
Heart Vessels. 2024 Jun;39(6):475-485. doi: 10.1007/s00380-024-02359-9. Epub 2024 Feb 21.
7
Lower levels of low-density lipoprotein cholesterol are associated with a lower prevalence of thin-cap fibroatheroma in statin-treated patients with coronary artery disease.
J Clin Lipidol. 2022 Jan-Feb;16(1):104-111. doi: 10.1016/j.jacl.2021.11.012. Epub 2021 Dec 4.
8
Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels.
Atherosclerosis. 2015 Oct;242(2):490-5. doi: 10.1016/j.atherosclerosis.2015.08.005. Epub 2015 Aug 8.
9
Pitavastatin: an overview.
Atheroscler Suppl. 2011 Nov;12(3):271-6. doi: 10.1016/S1567-5688(11)70886-8.
10
Pleiotropic Effects of Statins on the Cardiovascular System.
Circ Res. 2017 Jan 6;120(1):229-243. doi: 10.1161/CIRCRESAHA.116.308537.
引用本文的文献
1
A comprehensive analysis identifies and validates NPC1 as a potential biomarker for prognosis in HCC.
Front Genet. 2025 Aug 13;16:1588583. doi: 10.3389/fgene.2025.1588583. eCollection 2025.
2
MBTPS1: a membrane-bound transcription factor protease implicated in the pathogenesis of several skin and skeletal disorders.
Funct Integr Genomics. 2025 Aug 29;25(1):178. doi: 10.1007/s10142-025-01694-y.
3
Effects of Novel Nutraceutical Combination on Lipid Pattern of Subjects with Sub-Optimal Blood Cholesterol Levels.
Biomedicines. 2025 Aug 9;13(8):1948. doi: 10.3390/biomedicines13081948.
4
Machine Learning for Predicting Thromboembolic Events Following Flow Diverter Treatment of Intracranial Aneurysms: A Multicenter Retrospective Study.
Neurol Ther. 2025 Aug 27. doi: 10.1007/s40120-025-00808-9.
5
The causal effects of remnant cholesterol on increased risk of cardiovascular diseases in East Asians.
BMC Med. 2025 Aug 26;23(1):495. doi: 10.1186/s12916-025-04329-y.
6
Cholesterol homeostasis and pathway enrichment in post-revascularization recovery.
Biomed Eng Online. 2025 Aug 9;24(1):98. doi: 10.1186/s12938-025-01429-x.
7
Depot-Specific Roles for C/EBPα in White Adipose Tissue Development and Metabolism.
bioRxiv. 2025 Jul 26:2025.07.22.666007. doi: 10.1101/2025.07.22.666007.
8
Insights into Binding Mechanisms of Potential Inhibitors Targeting PCSK9 Protein via Molecular Dynamics Simulation and Free Energy Calculation.
Molecules. 2025 Jul 14;30(14):2962. doi: 10.3390/molecules30142962.
9
Cerebral Small Vessel Disease: Therapeutic Approaches Targeting Neuroinflammation, Oxidative Stress, and Endothelial Dysfunction.
Curr Issues Mol Biol. 2025 Mar 27;47(4):232. doi: 10.3390/cimb47040232.
10
Assessment of lipid parameters and its association with risk of stage 1 hypertension: a cohort study in middle-aged and elderly Chinese.
Aging (Albany NY). 2025 Jul 14;17(7):1868-1880. doi: 10.18632/aging.206280.
本文引用的文献
1
Inactivating mutations in NPC1L1 and protection from coronary heart disease.
N Engl J Med. 2014 Nov 27;371(22):2072-82. doi: 10.1056/NEJMoa1405386. Epub 2014 Nov 12.
2
Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.
Curr Atheroscler Rep. 2014 Sep;16(9):439. doi: 10.1007/s11883-014-0439-8.
3
Deaths: leading causes for 2010.
Natl Vital Stat Rep. 2013 Dec 20;62(6):1-96.
4
Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.
Circulation. 2013 Nov 5;128(19):2113-20. doi: 10.1161/CIRCULATIONAHA.113.004678. Epub 2013 Sep 6.
5
Mechanisms and cellular functions of intramembrane proteases.
Biochim Biophys Acta. 2013 Dec;1828(12):2797-800. doi: 10.1016/j.bbamem.2013.07.001. Epub 2013 Jul 4.
6
Combating the epidemic of heart disease.
JAMA. 2012 Dec 26;308(24):2624-5. doi: 10.1001/jama.2012.164971.
7
Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Circulation. 2012 Nov 13;126(20):2408-17. doi: 10.1161/CIRCULATIONAHA.112.144055. Epub 2012 Nov 5.
8
Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment.
Ann Hum Genet. 2012 Sep;76(5):387-401. doi: 10.1111/j.1469-1809.2012.00724.x.
9
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
Lancet. 2012 Aug 11;380(9841):581-90. doi: 10.1016/S0140-6736(12)60367-5. Epub 2012 May 17.
10
PCSK9 inhibition: the next statin?
J Am Coll Cardiol. 2012 Jun 19;59(25):2354-5. doi: 10.1016/j.jacc.2012.03.011. Epub 2012 Mar 31.
Zotero 插件